免疫系统
癌症研究
肿瘤微环境
免疫疗法
癌症免疫疗法
封锁
化学
T细胞
程序性细胞死亡
脱甲基酶
细胞
细胞生物学
免疫检查点
癌细胞
癌症
细胞周期检查点
免疫原性细胞死亡
免疫抑制
微泡
细胞生长
分泌物
细胞外
细胞信号
细胞周期
细胞凋亡
信号转导
药理学
外体
作者
Yu Zhao,Danyang Zhang,Lin Meng,Si‐Ming Shan,Chao Zhang,Zhenzhong Deng,Chao Han,Ling‐Yi Kong
标识
DOI:10.1016/j.apsb.2025.10.030
摘要
Programmed cell death protein-1/programmed cell death ligand-1 (PD1/PD-L1) blockade has shown promise in cancer therapy but remains limited by low response rates. Recent efforts have explored strategies to enhance immunotherapy efficacy. Histone lysine-specific demethylase 1 (LSD1) inhibition can enhance tumor immune responses by downregulating PD-L1 expression. Furthermore, PD-L1 in tumor cell-derived extracellular vesicles (EVs) contributes to the immunosuppressive tumor microenvironment (TME) and promotes immune evasion. Here, we found that LSD1 inhibition can mediate the rearrangement of PD-L1 on tumor cell surfaces, reduce the secretion of EVs and PD-L1 levels in the TME, and ultimately block the long-range immunosuppression caused by tumor cell-released EVs. Therefore, we developed a TME-targeted synergistic therapy system with a dual mechanism in which anti-PD1 therapy blocks immune checkpoints, and forsythiaside A (FA) acts as an LSD1 inhibitor to regulate EVs secretion. Additionally, CD4 + T cells can directly kill tumor cells by inducing G1/S cell cycle arrest. Ultimately, this system activates the tumor immune response within the TME, effectively inhibiting the growth of non-small cell lung cancer tumors. Our work highlights the signaling role of EVs and the capacity of CD4 + T cells to arrest the cell cycle, offering a new approach to enhance response to anti-PD1/PD-L1 therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI